These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12052143)

  • 41. The role of arylamine N-acetyltransferases in chronic degenerative diseases: Their possible function in the immune system.
    Hernández-González O; Herrera-Vargas DJ; Martínez-Leija ME; Zavala-Reyes D; Portales-Pérez DP
    Biochim Biophys Acta Mol Cell Res; 2022 Sep; 1869(9):119297. PubMed ID: 35588943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Interindividual differences in the reaction to drugs and poisons].
    Meyer UA
    Ther Umsch; 1992 Feb; 49(2):97-101. PubMed ID: 1553631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on the pharmacogenetics of NATs: structural considerations.
    Stanley LA; Sim E
    Pharmacogenomics; 2008 Nov; 9(11):1673-93. PubMed ID: 19018723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Molecular pharmacology of polymorphic arylamine N-acetyltransferase involved in the metabolism of arylamine drugs].
    Deguchi T
    Nihon Rinsho; 1992 Apr; 50(4):877-86. PubMed ID: 1619774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic polymorphisms of drug metabolism.
    Meyer UA; Zanger UM; Skoda RC; Grant D; Blum M
    Prog Liver Dis; 1990; 9():307-23. PubMed ID: 2156298
    [No Abstract]   [Full Text] [Related]  

  • 46. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. N-acetyltransferase 2 polymorphism in patients with diabetes mellitus.
    Yalin S; Hatungil R; Tamer L; Ates NA; Dogruer N; Yildirim H; Karakas S; Atik U
    Cell Biochem Funct; 2007; 25(4):407-11. PubMed ID: 16397907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxyarylamine O-acetyltransferase in Syrian inbred hamster intestine and colon. Identity with the hepatic acetylation polymorphism.
    Ogolla F; Ferguson RJ; Kirlin WG; Trinidad A; Andrews AF; Mpezo M; Hein DW
    Drug Metab Dispos; 1990; 18(5):680-5. PubMed ID: 1981720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.
    Hirvonen A
    Environ Health Perspect; 1999 Feb; 107 Suppl 1(Suppl 1):37-47. PubMed ID: 10229705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N-acetyltransferase 2 phenotype may be associated with susceptibility to age-related cataract.
    Tamer L; Yilmaz A; Yildirim H; Ayaz L; Ates NA; Karakas S; Oz O; Yildirim O; Atik U
    Curr Eye Res; 2005 Oct; 30(10):835-9. PubMed ID: 16251120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
    Tsirka T; Boukouvala S; Agianian B; Fakis G
    Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular basis for differences in susceptibility to toxicants: introduction.
    Boobis AR
    Toxicol Lett; 1992 Dec; 64-65 Spec No():109-13. PubMed ID: 1471164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical relevance of drug metabolism polymorphisms].
    Mikus G
    Ther Umsch; 2000 Sep; 57(9):573-8. PubMed ID: 11036438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic polymorphisms in drug metabolism--its relevance to Asian populations.
    Lee EJ
    Ann Acad Med Singap; 1991 Jan; 20(1):56-60. PubMed ID: 2029165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug metabolism polymorphisms as modulators of cancer susceptibility.
    Taningher M; Malacarne D; Izzotti A; Ugolini D; Parodi S
    Mutat Res; 1999 May; 436(3):227-61. PubMed ID: 10354524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.
    Morrison A; Levy R
    Pharmacogenomics; 2004 Sep; 5(6):673-89. PubMed ID: 15335288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reactions and enzymes in the metabolism of drugs and other xenobiotics.
    Testa B; Pedretti A; Vistoli G
    Drug Discov Today; 2012 Jun; 17(11-12):549-60. PubMed ID: 22305937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics.
    Ingelman-Sundberg M
    Arch Toxicol Suppl; 1997; 19():3-13. PubMed ID: 9079190
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacogenetics and adverse drug reactions.
    Meyer UA
    Lancet; 2000 Nov; 356(9242):1667-71. PubMed ID: 11089838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. N-acetyltransferases: lessons learned from eighty years of research.
    Agúndez JA
    Curr Drug Metab; 2008 Jul; 9(6):463-4. PubMed ID: 18680465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.